Description
Anti-TROP-2 Antibody, Non-Fucosylated (BioBet-1831ZP) is a chimeric monoclonal IgG1, low fucose content antibody against TROP-2. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Triple-neg. breast cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TROP-2 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TACSTD2
Full Name
Tumor-associated calcium signal transducer 2
Background
Tumor-associated calcium signal transducer 2, also known as Trop-2 and as epithelial glycoprotein-1 antigen (EGP-1), is a protein that in humans is encoded by the TACSTD2 gene.
This intronless gene encodes a carcinoma-associated antigen defined by the monoclonal antibody GA733. This antigen is a member of a family including at least two type I membrane proteins. It transduces an intracellular calcium signal and acts as a cell surface receptor.
Alternative Names
TACSTD2, EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1, TROP2, tumor-associated calcium signal transducer 2, tumor associated calcium signal transducer 2
Gene ID
Human: 4070; Mouse: 56753
UniProt ID
Human: P09758; Mouse: Q8BGV3
Genecards
TACSTD2
Involvement in Disease
Diseases associated with TACSTD2 include Corneal Dystrophy, Gelatinous Drop-Like and Lattice Corneal Dystrophy. Among its related pathways are Ca, cAMP and Lipid Signaling and Adhesion.
Function
May act as growth factor receptors.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, low fucose content
Antibody Clone
BioBet-1831ZP
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Antibody Indication
Triple-neg. breast cancer
Triple-neg. breast cancer
